85Sr bone scan in neoplastic disease

Gerald L Denardo, Sally J. Jacobson, Antolin Raventos

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The skeleton is a frequent site of metastases from neoplasms that are primary elsewhere. Bone scanning was introduced in 1961 to detect enhanced localization of 85Sr at the sites of skeletal abnormalities. After 10 yr of experience with the bone scan, certain conclusions can be proposed. The bone scan is not helpful in the evaluation of diseases that diffusely affect the skeleton, but it is a sensitive method for detecting diseases that elicit a localized reparative reaction of the skeleton. Approximately 10-40% of patients with skeletal metastases have a normal skeletal roentgenogram at a time when the bone scan is abnormal, whereas less than 5% of bone scans are normal at a time when the skeletal roentgenogram reveals localized abnormalities. False positive bone scans can be reduced to considerably less than 1% through a knowledge of the mechanisms of localization of 85Sr. The bone scan is particularly useful in patients with lymphomatous diseases and carcinoma of the lung, prostate, breast, and oropharynx. The serum alkaline and acid phosphatases are not sensitive enough for the detection of skeletal metastases. The primary limitation of bone scanning has been, and to some extent remains, the length of time required to accomplish the technical portion of the procedure. However, improved instrumentation and short-lived radiopharmaceuticals promise to make bone scanning feasible as a survey procedure. A certain amount of caution is still in order before accepting short-lived radiopharmaceuticals as a replacement for 85Sr.

Original languageEnglish (US)
Pages (from-to)18-30
Number of pages13
JournalSeminars in Nuclear Medicine
Volume2
Issue number1
DOIs
StatePublished - 1972

Fingerprint

Bone and Bones
Skeleton
Radiopharmaceuticals
Neoplasm Metastasis
Neoplasms by Site
Oropharynx
Acid Phosphatase
Lung Diseases
Alkaline Phosphatase
Prostate
Breast
Carcinoma
Serum

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

85Sr bone scan in neoplastic disease. / Denardo, Gerald L; Jacobson, Sally J.; Raventos, Antolin.

In: Seminars in Nuclear Medicine, Vol. 2, No. 1, 1972, p. 18-30.

Research output: Contribution to journalArticle

Denardo, Gerald L ; Jacobson, Sally J. ; Raventos, Antolin. / 85Sr bone scan in neoplastic disease. In: Seminars in Nuclear Medicine. 1972 ; Vol. 2, No. 1. pp. 18-30.
@article{97eacf67c0c344c68e6878e5c418ace8,
title = "85Sr bone scan in neoplastic disease",
abstract = "The skeleton is a frequent site of metastases from neoplasms that are primary elsewhere. Bone scanning was introduced in 1961 to detect enhanced localization of 85Sr at the sites of skeletal abnormalities. After 10 yr of experience with the bone scan, certain conclusions can be proposed. The bone scan is not helpful in the evaluation of diseases that diffusely affect the skeleton, but it is a sensitive method for detecting diseases that elicit a localized reparative reaction of the skeleton. Approximately 10-40{\%} of patients with skeletal metastases have a normal skeletal roentgenogram at a time when the bone scan is abnormal, whereas less than 5{\%} of bone scans are normal at a time when the skeletal roentgenogram reveals localized abnormalities. False positive bone scans can be reduced to considerably less than 1{\%} through a knowledge of the mechanisms of localization of 85Sr. The bone scan is particularly useful in patients with lymphomatous diseases and carcinoma of the lung, prostate, breast, and oropharynx. The serum alkaline and acid phosphatases are not sensitive enough for the detection of skeletal metastases. The primary limitation of bone scanning has been, and to some extent remains, the length of time required to accomplish the technical portion of the procedure. However, improved instrumentation and short-lived radiopharmaceuticals promise to make bone scanning feasible as a survey procedure. A certain amount of caution is still in order before accepting short-lived radiopharmaceuticals as a replacement for 85Sr.",
author = "Denardo, {Gerald L} and Jacobson, {Sally J.} and Antolin Raventos",
year = "1972",
doi = "10.1016/S0001-2998(72)80004-7",
language = "English (US)",
volume = "2",
pages = "18--30",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - 85Sr bone scan in neoplastic disease

AU - Denardo, Gerald L

AU - Jacobson, Sally J.

AU - Raventos, Antolin

PY - 1972

Y1 - 1972

N2 - The skeleton is a frequent site of metastases from neoplasms that are primary elsewhere. Bone scanning was introduced in 1961 to detect enhanced localization of 85Sr at the sites of skeletal abnormalities. After 10 yr of experience with the bone scan, certain conclusions can be proposed. The bone scan is not helpful in the evaluation of diseases that diffusely affect the skeleton, but it is a sensitive method for detecting diseases that elicit a localized reparative reaction of the skeleton. Approximately 10-40% of patients with skeletal metastases have a normal skeletal roentgenogram at a time when the bone scan is abnormal, whereas less than 5% of bone scans are normal at a time when the skeletal roentgenogram reveals localized abnormalities. False positive bone scans can be reduced to considerably less than 1% through a knowledge of the mechanisms of localization of 85Sr. The bone scan is particularly useful in patients with lymphomatous diseases and carcinoma of the lung, prostate, breast, and oropharynx. The serum alkaline and acid phosphatases are not sensitive enough for the detection of skeletal metastases. The primary limitation of bone scanning has been, and to some extent remains, the length of time required to accomplish the technical portion of the procedure. However, improved instrumentation and short-lived radiopharmaceuticals promise to make bone scanning feasible as a survey procedure. A certain amount of caution is still in order before accepting short-lived radiopharmaceuticals as a replacement for 85Sr.

AB - The skeleton is a frequent site of metastases from neoplasms that are primary elsewhere. Bone scanning was introduced in 1961 to detect enhanced localization of 85Sr at the sites of skeletal abnormalities. After 10 yr of experience with the bone scan, certain conclusions can be proposed. The bone scan is not helpful in the evaluation of diseases that diffusely affect the skeleton, but it is a sensitive method for detecting diseases that elicit a localized reparative reaction of the skeleton. Approximately 10-40% of patients with skeletal metastases have a normal skeletal roentgenogram at a time when the bone scan is abnormal, whereas less than 5% of bone scans are normal at a time when the skeletal roentgenogram reveals localized abnormalities. False positive bone scans can be reduced to considerably less than 1% through a knowledge of the mechanisms of localization of 85Sr. The bone scan is particularly useful in patients with lymphomatous diseases and carcinoma of the lung, prostate, breast, and oropharynx. The serum alkaline and acid phosphatases are not sensitive enough for the detection of skeletal metastases. The primary limitation of bone scanning has been, and to some extent remains, the length of time required to accomplish the technical portion of the procedure. However, improved instrumentation and short-lived radiopharmaceuticals promise to make bone scanning feasible as a survey procedure. A certain amount of caution is still in order before accepting short-lived radiopharmaceuticals as a replacement for 85Sr.

UR - http://www.scopus.com/inward/record.url?scp=0015259064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015259064&partnerID=8YFLogxK

U2 - 10.1016/S0001-2998(72)80004-7

DO - 10.1016/S0001-2998(72)80004-7

M3 - Article

C2 - 4501055

AN - SCOPUS:0015259064

VL - 2

SP - 18

EP - 30

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 1

ER -